Moderna and Merck developed a personalized mRNA vaccine that prevented melanoma from returning in a late-stage Phase 3 clinical trial.
This development represents a potential shift in oncology by using a patient's own tumor mutations to train the immune system to fight cancer.
The trial enrolled approximately 150 patients with high-risk melanoma [1]. Participants received the personalized mRNA vaccine in combination with Keytruda, an immunotherapy drug produced by Merck. The treatment aimed to provide a disease-free survival benefit by targeting the unique genetic markers of each patient's tumor [1], [2].
Data from the study showed a 44% reduction in the risk of melanoma recurrence [1]. Furthermore, the combined therapy resulted in a 57% reduction in the risk of death [1]. These results were announced this week in a press release on Wednesday, Aug. 21 [1], [2].
"These results represent a major step forward in the fight against melanoma and demonstrate the power of personalized mRNA immunotherapy," Robert Davis, CEO of Merck, said [2].
The multi-center trial was conducted at various sites across the U.S. and other countries [1]. By tailoring the vaccine to the specific mutations of an individual's cancer, the researchers sought to create a more precise immune response than traditional therapies allow [1], [2].
"We are thrilled with the data and look forward to bringing this vaccine to patients who need it most," Stéphane Bancel, CEO of Moderna, said [1].
Financial markets responded positively to the clinical success. Following the announcement, Moderna's stock rose between 10% and 12% [3], [2].
“44% reduction in risk of melanoma recurrence”
The success of this trial validates the application of mRNA technology beyond infectious diseases and into personalized oncology. By combining a custom-built vaccine with existing immunotherapy, the treatment targets the specific genetic profile of a patient's tumor, potentially reducing the high recurrence rates associated with aggressive skin cancers.
